The biological impact of 1,25-dihydroxyvitamin D3 on cellular proliferation and differentiation and on mature cell function is typical of most steroid-like hormones. Not surprisingly, the mechanism by which the vitamin/hormone functions is also similar. The central role of the vitamin D receptor (VDR) in transducing systemic 1,25-dihydroxyvitamin D3 signals into the target cell nucleus is now well recognized. Despite these insights, it is clear that vitamin D through its receptor exerts highly selective actions on both cells and genes, activities that are dependent upon additional nuclear protein components that function in highly cell- and gene promoter-selective ways. The goal of this project is to further define both general as well as specific features of the vitamin D signaling pathway, features that determine tissue-selective action.
The Specific Aims of the project are to: 1) establish the validity and characterize the nature of the VDR modulatory unit (VDR-MU); 2) identify and characterize comodulating amplifiers and/or repressors; and 3) clarify the mechanism by which the inducing actions of vitamin D3 are integrated with other incoming extracellular signals to regulate the expression of human osteocalcin and 24OHase genes. Advanced yeast genetic selection systems will be used to characterize the VDR-MU as well as to identify comodulators of vitamin D3 action. Human homologues will be identified through standard cloning techniques. Both cell transfection and biochemical assays will be utilized to examine the activity of mutant VDRs, cofactor enhancement or repression of these activities, and modulation by unique retinoid receptor ligands. The natural human osteocalcin and 24OHase promoters will be utilized in transiently and stably transfected cells to examine at the promoter level the integration of multiple signaling pathways on vitamin D action. The therapeutic value of 1,25(OH)2D3 in a variety of pathophysiological states has been demonstrated. Moreover, newly synthesized analogues show promise for the treatment of hyperproliferative disorders that are either dermatologic and/or oncologic in nature. Nevertheless, identification of the proteins and mechanism by which selectivity is generated will enhance our understanding of the specific actions of current compounds and enable discovery of new vitamin D analogues and mimetics that exhibit even greater potency, efficacy and tissue selectivity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK052453-02
Application #
2713452
Study Section
Special Emphasis Panel (ZRG4-GMB (04))
Program Officer
Margolis, Ronald N
Project Start
1997-06-25
Project End
2002-05-31
Budget Start
1998-06-15
Budget End
1999-05-31
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Cincinnati
Department
Physiology
Type
Schools of Medicine
DUNS #
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Fretz, Jackie A; Zella, Lee A; Kim, Sungtae et al. (2007) 1,25-Dihydroxyvitamin D3 induces expression of the Wnt signaling co-regulator LRP5 via regulatory elements located significantly downstream of the gene's transcriptional start site. J Steroid Biochem Mol Biol 103:440-5
Zella, Lee A; Chang, Ching-Yi; McDonnell, Donald P et al. (2007) The vitamin D receptor interacts preferentially with DRIP205-like LxxLL motifs. Arch Biochem Biophys 460:206-12
Pike, J Wesley; Meyer, Mark B; Watanuki, Makoto et al. (2007) Perspectives on mechanisms of gene regulation by 1,25-dihydroxyvitamin D3 and its receptor. J Steroid Biochem Mol Biol 103:389-95
Meyer, Mark B; Watanuki, Makoto; Kim, Sungtae et al. (2006) The human transient receptor potential vanilloid type 6 distal promoter contains multiple vitamin D receptor binding sites that mediate activation by 1,25-dihydroxyvitamin D3 in intestinal cells. Mol Endocrinol 20:1447-61
Kim, Sungtae; Shevde, Nirupama K; Pike, J Wesley (2005) 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts. J Bone Miner Res 20:305-17
Pike, J Wesley; Pathrose, Peterman; Barmina, Olga et al. (2003) Synthetic LXXLL peptide antagonize 1,25-dihydroxyvitamin D3-dependent transcription. J Cell Biochem 88:252-8
Yamamoto, Hironori; Shevde, Nirupama K; Warrier, Anjali et al. (2003) 2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts. J Biol Chem 278:31756-65
Pathrose, Peterson; Barmina, Olga; Chang, Ching-Yi et al. (2002) Inhibition of 1,25-dihydroxyvitamin D3-dependent transcription by synthetic LXXLL peptide antagonists that target the activation domains of the vitamin D and retinoid X receptors. J Bone Miner Res 17:2196-205
Shevde, Nirupama K; Plum, Lori A; Clagett-Dame, Margaret et al. (2002) A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation. Proc Natl Acad Sci U S A 99:13487-91